Fri, Nov 28, 2014, 1:53 AM EST - U.S. Markets open in 7 hrs 37 mins


% | $
Quotes you view appear here for quick access.

VIVUS Inc. Message Board

  • friedaynt friedaynt Jan 10, 2013 8:33 PM Flag

    Everyday has the potential for $10-$20 pop

    Focus on the facts.

    STENDRA is approved, and will be partnered or sold any day. The drug works faster than any other ED drug on the market. This is an obvious winner, and VVUS longs will benefit soon.

    QSYMIA has way better efficacy then belvig or contrave. In fact, belvig wasn't much better than the placebo. I hope belvig gets a lot of traffic when it hits the market, because obese people will switch to QSYMIA after a month or 2 of disappointing results. People want results fast, and QSYMIA is the only answer, and that is why it is gaining HUGE popularity. Couple that with insurance companies covering a larger portion and we have a great situation for the obese population.

    QSYMIA had a bit of a challenging start. Managements questionable actions after FDA approval got us off to a slow start. In other words, just because the drug was approved there is a lot of work still to be done. Getting doctors on board, getting the word out, getting customers educated, working with insurance companies, trying to partner or sell the drug, etc., etc. Management has finally broke through, and they are gaining huge momentum. I'm expecting big things in the very near future. Shorts on this board are desperate and have the same BS story on every post. No facts, no clue. They are just working for hedge funds, and the more meaningless post they write, gives me more confidence in VVUS, as they are scared of the inevitable. BUYOUT!

    C U all higher.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.35+0.03(+0.90%)Nov 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.